Literature DB >> 17595318

Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor.

Susana Masiá1, Susana Alvarez, Angel R de Lera, Domingo Barettino.   

Abstract

Retinoic acid (RA) treatment of SH-SY5Y neuroblastoma cells results in activation of phosphatidylinositol-3-kinase (PI3K) signaling pathway, and this activation is required for RA-induced differentiation. Here we show that RA activates PI3K and ERK1/2 MAPK signaling pathways through a rapid, nongenomic mechanism that does not require new gene transcription or newly synthesized proteins. Activation of PI3K by RA appears to involve the classical nuclear receptor, retinoic acid receptor (RAR), on the basis of the pharmacological profile of the activation, loss, and gain of function experiments with mouse embryo fibroblast-RAR(alpha beta gamma)(L-/L-) null cells, and the physical association between liganded RAR and PI3K activity. The association of RAR with the two subunits of PI3K was differentially regulated by the ligand. Immunoprecipitation experiments performed in SH-SY5Y cells showed stable association between RARalpha and p85, the regulatory subunit of PI3K, independently of the presence of RA. In contrast, ligand administration increased the association of p110, the catalytic subunit of PI3K, to this complex. The intracellular localization of RAR proved to be relevant for PI3K activation. A chimerical RAR fusing c-Src myristylation domain to the N terminus of RARalpha (Myr-RARalpha) was targeted to plasma membrane. Transfection of Myr-RARalpha to mouse embryo fibroblast-RAR(alpha beta gamma)(L-/L-) null cells and COS-7 cells results in strong activation of the PI3K signaling pathway, although both in the absence as well in the presence of RA. Our results support a mechanism in which ligand binding to RAR would play a major role in the assembly and intracellular location of a signaling complex involving RAR and the subunits of PI3K.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595318     DOI: 10.1210/me.2007-0062

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  72 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

2.  Retinoic acid orchestrates fibroblast growth factor signalling to drive embryonic stem cell differentiation.

Authors:  Marios P Stavridis; Barry J Collins; Kate G Storey
Journal:  Development       Date:  2010-03       Impact factor: 6.868

3.  Retinol induces morphological alterations and proliferative focus formation through free radical-mediated activation of multiple signaling pathways.

Authors:  Daniel Pens Gelain; Matheus Augusto de Bittencourt Pasquali; Fernanda Freitas Caregnato; Mauro Antonio Alves Castro; José Claudio Fonseca Moreira
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

4.  Combinatorial knockout of RARα, RARβ, and RARγ completely abrogates transcriptional responses to retinoic acid in murine embryonic stem cells.

Authors:  Kristian B Laursen; Lorraine J Gudas
Journal:  J Biol Chem       Date:  2018-05-30       Impact factor: 5.157

5.  A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters.

Authors:  Nathalie Bruck; Dominique Vitoux; Christine Ferry; Vanessa Duong; Annie Bauer; Hughes de Thé; Cécile Rochette-Egly
Journal:  EMBO J       Date:  2008-12-11       Impact factor: 11.598

6.  A role for retinoic acid in homeostatic plasticity.

Authors:  Rachel D Groth; Richard W Tsien
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

Review 7.  Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.

Authors:  William S Blaner
Journal:  Pharmacol Ther       Date:  2019-01-29       Impact factor: 12.310

Review 8.  Vitamin A and retinoid signaling: genomic and nongenomic effects.

Authors:  Ziad Al Tanoury; Aleksandr Piskunov; Cécile Rochette-Egly
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

Review 9.  Retinoids and rexinoids in cancer prevention: from laboratory to clinic.

Authors:  Iván P Uray; Ethan Dmitrovsky; Powel H Brown
Journal:  Semin Oncol       Date:  2015-09-25       Impact factor: 4.929

10.  Mammalian target of rapamycin complex 1 (mTORC1) Is required for mouse spermatogonial differentiation in vivo.

Authors:  Jonathan T Busada; Bryan A Niedenberger; Ellen K Velte; Brett D Keiper; Christopher B Geyer
Journal:  Dev Biol       Date:  2015-08-05       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.